SlideShare a Scribd company logo
Presenter – Dr. Roohana Hasan JR3
Moderator- Dr.Afroz Abidi
OVERVIEW
 Definition
 Etiology
 Pathophysiology
 Pharmacological Agents used in Alzheimers
Disease
In vitro Models
1. In Vitro Inhibition of AcetylcholineEsterase Activity in
Rat Striatum
2. In Vitro Inhibition of ButyrylcholineEsterase Activity in
Human Serum
3. [3H]N-Methylscopolamine Binding in the Presence and
Absence of Gpp(NH)p
4. Stimulation of Phosphatidylinositol Turnover in Rat
Brain Slices
5. [3H]N-Methylcarbamylcholine Binding to Nicotinic
Cholinergic Receptors in Rat Frontal Cortex
6. Uncompetitive NMDA Receptor Antagonism.
Models for Alzheimers
Disease
OVERVIEW
1. Step Down.
2. Step through.
3. Scopolamine induced amnesia
in mice.
4. Two Compartment Test
5. Up Hill Avoidance
In vivo Models
1. Shuttle Box
Avoidance (Two-
Way Shuttle Box)
2. Jumping Avoidance
(One-Way Shuttle
Box)
3. Runway Avoidance
1. Open Field
Test
2. Radial Arm
Maze
3. Y- maze
4. Morris water
Maze
1. Conditioned
Nictitating
Membrane
Response in
Rabbits
2. Automated
Learning and
Memory Model in
Mice
1. Tau models
2. Aβ-tau axis
3. Secretase
models
4. APOE models
5. Axonal
transport
Passive
Avoidance
Active
Avoidance
Discrimination
Learning
Conditioned
Responses
Genetic
Models
INTRODUCTION
 Alzheimer's disease (AD) is the most common neurodegenerative
disease which has features of progressive impairments in memory,
behaviour and cognition and can lead to death.
 In addition to the financial burden of AD on health care system, the
disease has powerful emotional impact on caregivers and families
of those afflicted.
Etiology and Risk
factors
 Strong genetic
component
 Gender – women, ?
Estrogen
 Tobacco
 Head injury
 Obesity
 Hypertension
 Diabetes
 Elevated serum
cholesterol
 Elevated serum
homocysteine
 Depression
 Lack of intellectual
stimulation/education
1. Extracellular deposition of ß-
amyloid (Aß) plaques
2. Intraneuronal neurofibrillary
tangles.
3. Loss of cortical cholinergic
neurones in AD probably
accounts for memory impairment.
Pathological Hallmarks of
Alzheimer’s Disease
Formation of plaques and neurofibrillary tangles in
Alzheimer’s disease, and sites of action of future
drug treatments
SCREENING
Models
Of
Alzheimer’s
Disease
Inhibitory (Passive)
Avoidance
 One of the most common
animal tests in memory research
is the inhibition to imitate
activities or learned habits.
The term “passive avoidance” is
usually employed to describe
experiments in which the animal
learns to avoid a noxious event
by suppressing a particular
Purpose and
Ratinale
Step-down METHOD
 An animal (mouse or rat) in an open
field spends most of the time close to
the walls and in the corners.
 When placed on an elevated platform
in the center of a rectangular
compartment, it steps down almost
immediately to the floor to explore the
enclosure and to approach the wall.
Mice or rats of either sex are
used.
A rectangular box (50 × 50 cm)
with electrifiable grid floor and
35 cm fits over the block.
The grid floor is connected to a
shock device, which delivers
scrambled foot shocks. The
actual experiments can be
performed in different ways.
PROCEDURE:
Familiarization: The animal is placed on the platform,
released after raising the cylinder, and the latency to
descend is measured. After 10 s of exploration, it is
returned to the home cage.
Learning: Immediately after the animal has descended
from the platform an unavoidable footshock is applied
(Footshock: 50 Hz; 1.5 mA; 1 s) and the animal is
returned to the home cage
Retention Test: 24 h after the learning trial the animal is
again placed on the platform and the stepdown latency
is measured. The test is finished when the animal steps
down or remains on the platform (cutoff time: 60 s).
EVALUATION:
The time of descent during the
learning phase and the time during
the retention test is measured.
A prolongation of the step-down
latency is defined as learning.
MODIFICATIONS OF THIS
METHOD:
One of the most common
modifications is to
induce amnesia in
animals.
There are different
methods to do so
including
Electroconvulsive shock
Scopolamine
Alcohol
STEP THROUGH METHOD
 This test uses normal behavior of mice and rats.
These animals avoid bright light and prefer dim
illumination.
 When placed into a brightly illuminated space
connected to a dark enclosure, they rapidly enter the
dark compartment and remain there.
The standard technique was developed for mice by
Jarvik and Kopp (1967) and modified for rats by King
and Glasser (1970)
PURPOSE AND
RATIONALE
PROCEDURE: Mice and rats of either sex are used.
The test apparatus consists of a small
chamber connected to a larger dark
chamber via a guillotine door.
The test animals are given an
acquisition trial followed by a
retention trial 24 h later. In the
acquisition trial the animal is placed
in the illuminated compartment at a
maximal distance from the guillotine
door, and the latency to enter the
dark compartment is measured.
Animals that do not step
through the door within a
cut-off time: 90 s (mice) or
180 s (rats) are not used.
 Immediately after the
animal enters the dark
compartment, the door is
shut automatically and
an unavoidable
footshock (Footshock: 1
mA; 1 s – mice; 1.5 mA; 2
s – rat) is delivered.
 The animal is then
quickly removed (within
10 s) from the apparatus
and put back into its
home cage.
 The test procedure is
repeated with or without
EVALUATION:
 The time to step-through during the learning
phase is measured and the time during the
retention test is measured.
 In this test a prolongation of the step-
through latencies is specific to the
experimental situation.
 An increase of the step-through latency is
defined as learning.
UP HILL AVOIDANCE METHOD
 Many animal species exhibit a negative
geotaxis, i. e. the tendency to orient and move
towards the top when placed on a slanted
surface.
 When placed on a tilted platform with head
facing down-hill, rats and mice invariably turn
around and move rapidly up the incline.
PURPOSE AND
RATIONALE:
PROCEDURE
Rats of both sex were used and
maintained under standard
conditions. The experimental
apparatus is a 50 × 50 cm box
with 35 cm high opaque plastic
walls.
The box can be inclined at different
angles. The floor consists of 10 mm
diameter stainless steel grid bars
placed 13 mm apart.
To deliver the tail-shock, a
tailelectrode is constructed,
consisting of a wire clip
connected to a constant current
shock source. The animal is
first fitted with the tail-electrode
and then placed onto the grid
with its nose facing down
During baseline-trials the animal’s latency to make a
180° turn and initiate the first climbing response is
measured. Thereafter the animal is returned to its
home cage.
During the experimental trials the latencies are
measured and additionally a tail-shock (1.5 or 2 mA)
was administered contingent on the first climbing
response after the 180° turn
Immediately after the shock the animal is placed in its
home cage. Retest is performed 24 h later
EVALUATION:
 The latencies are measured.
CRITICAL ASSESSMENT OF THE
METHOD
 The up-hill avoidance technique promises to
provide a useful addition to the existing arsenal
of inhibitory (passive) avoidance methods.
 Its most obvious advantage is that it can be
administered to animals debilitated in sensory-
motor coordination by pharmacological or
surgical treatments that would preclude use of
Scopolamine-Induced
Amnesia in Mice
 The administration of the antimuscarinic agent
scopolamine to young human volunteers produces
transient memory deficits.
Scopolamine has been shown to impair memory
retention when given to mice shortly before training in
a dark avoidance task.
The ability of a range of different cholinergic agonist
drugs to reverse the amnesic effects of scopolamine is
PURPOSE AND
RATIONALE
The scopolamine test is performed in groups of 10
male NMRI mice weighing 26–32 g in a one-trial,
passive avoidance paradigm.
Five min after i.p. administration of 3 mg/kg
scopolamine hydrobromide, each mouse is
individually placed in the bright part of a
twochambered apparatus for training. After a brief
orientation period, the mouse enters the second,
darker chamber.
Once inside the second chamber, the door is closed
which prevents the mouse from escaping, and a 1 mA,
1-s foot shock is applied through the grid floor. The
mouse is then returned to the home cage.
Procedure
Twenty-four hours later, testing is performed
by placing the animal again in the bright
chamber.
The latency in entering the second darker
chamber within a 5 min test session is
measured electronically
Whereas untreated control animals enter the darker
chamber in the second trial with a latency of about 250
s, treatment with scopolamine reduces the latency to 50
s.
The test compounds are administered 90 min before
training. A prolonged latency indicates that the animal
remembers that it has been punished and, therefore,
does avoid the darker chamber.
EVALUATION:
Using various doses latencies after treatment
with test compounds are expressed as
percentage of latencies in mice treated with
scopolamine only.
In some cases, straight dose-response
curves can be established whereas with other
drugs inverse U-shaped dose-responses are
observed.
MODIFICATION:
Yang et al. (2004) induced learning and memory
impairment in mice by treatment with 1-methyl-4- phenyl-
1,2,3,6-tetrahydropyridine (MPTP).
Active Avoidance
As in other instrumental conditioning paradigms the
animal learns to control the administration of the
unconditioned stimulus by appropriate reactions to
the conditioned stimulus preceding the noxious
stimulus.
The first stage of avoidance learning is usually
escape, whereby a reaction terminates the
Active avoidance learning is a
fundamental behavioral
phenomenon
Runway Avoidance
 A straightforward avoidance situation features a fixed
aversive gradient which can be traversed by the
animal.
 The shock can be avoided when the safe area is
reached within the time allocated.
PURPOSE AND
RATIONALE:
PROCEDURE:
The same box as used in the
step-through model can be used
in this experiment
Mice or rats of either sex are used and
maintained under standard conditions
and handled for several days before
the experiment.
The apparatus is uniformly
illuminated by an overhead light
source. A loudspeaker, mounted
50 cm above the start-box,
serves for presenting the
acoustic conditioned stimulus
The footshock is employed by
the same source as in the step-
through avoidance
The animal is allowed to explore the whole
apparatus for 5 min. The guillotine door is
then closed and the animal is placed into the
light starting area.
After 10 s the acoustic CS is applied and the door is
simultaneously opened. Shock is turned on after 5 s. The
CS continuous until the animal reaches the safe area.
It is left there for 50–70 s (intertrial interval, ITI) before
returned to the same area again
The procedure starts again. The training is continued
until the animal attains the criterion of 9 avoidances in
10 consecutive trials.
On the next day the procedure is repeated until the
same learning criterion is reached. The time needed to
reach the safe area is measured..
EVALUATION:
 The time the animal needs to reach the safe area on
both days is measured.
 In addition, the number of errors (not reaching the
safe area) is recorded.
Jumping Avoidance
(One-Way Shuttle Box)
PURPOSE AND
RATIONALE:
 In order to enhance the start-goal
distinction a vertical gradient is
introduced which requires the
animal to perform a discrete
response of an all-or-none character,
such as the jump, which clearly
differs from the more continuous
translational movements required in
PROCEDURE:
Rats of both sex are used and
maintained under standard
conditions. The apparatus used
consists of a rectangular box 40 × 25
cm with 40 cm high metal walls, an
electrifiable grid floor and a Plexiglas
ceiling.
A 12 × 12 × 25 cm opaque plastic
pedestrial, mounted onto one of the
narrow walls of the box provides the
isolated goal area
Flush with the horizontal surface of
the pedestal moves a vertical barrier,
which can either be retracted to the
rear wall of the apparatus to expose
the goal area or pushed forward to
block access to the goal completely
The animal is placed into the apparatus for 5
min with the goal area exposed (barrier
retracted). The barrier is then moved forwards
and the goal is blocked for 2 s.
The first trial starts by exposing the goal area and
applying an acoustic CS (1000 Hz, 85 dB). Electric
shocks – US (1.0 mA; 50 Hz; 0.5 s) – are applied 5 s later
(once per 2 s), and continued together with the CS until
the animal jumps onto the platform.
After 30 s the barrier pushes the animal off the platform
onto the grid floor. The sequence is repeated until the
criterion of 10 consecutive avoidances is reached.
Retention is tested on the next day until the animal
reaches criterion.
EVALUATION:
 The time the animal needs to reach the safe area on
both days is measured.
 In addition, the number of errors (not reaching the
safe area) is recorded.
Discrimination
Learning
Spatial Habituation Learning
Open Field Test
PURPOSE AND
RATIONALE:
 The open-field test utilizes the natural tendency of rodents
to explore novel environments in order to open up new
nutrition, reproduction and lodging resources.
 Spatial habituation learning is defined as a decrement in
reactivity to a novel environment after repeated exposure
to that now familiar environment.
 This reduction in exploratory behaviors during re-
exposures is interpreted in terms of remembering or
recognition of the specific physical characteristics of the
PROCEDURE: The open-field apparatus is a
rectangular chamber made of painted
wood or grey PVC.
A 25 W red or green light bulb is
placed either directly above or
beneath the maze to achieve an
illumination density at the centre of
approximately 0.3 lx.
Masking noise is provided by a
broad spectrum noise
generator (60 dB). Prior to each
trial, the apparatus is swept out
with water containing 0.1%
acetic acid
Housing room and the testing location are
separated and animals are transported to the testing
room 30 min before testing
The digitized image of the path taken by each animal
is stored.
In aged or hypoactive rodents testing is performed
during the animals dark phase of day
The rodent is placed on the center or in a corner of the
open-field for 5–10 minute sessions (mice: up to 20
min, because of the high basal activity level).
The animals are re-exposed to the openfield 24 and 96
h after the initial trial
EVALUATION:
 The exploratory behaviours registered are:
 Rearings or vertical activity: the number of times
an animal was standing on its hind legs with
forelegs in the air or against the wall.
 The duration of single rearings as a measure of
non-selective attention.
 Locomotion or horizontal activity: the distance in
centimeters an animal moved.
Y-Maze
PURPOSE AND
RATIONALE:
 Measures spatial working memory. It has
been designed to make the animal to learn to
discriminate between two arms: one
illuminated , without shock and other non
illuminated with shock and learn to reach the
correct arm,the illuminated one.
 These kind of experiments are known as
Simultaneous Discrimination Learning.
PROCEDURE: The naive animal will be
allowed to explore the Y maze
apparatus for 5minutes at the
start of training session. The
rat will then be put into the
starting chamber.
After approximately 5seconds,
shock will be applied by
switching the unit on or by
rotary program selector till the
animal reaches the goal in
illuminated arm.
The animal will then be allowed to stay in
that arm for entire inter-trial period.
The next program will be selected and the process
will be repeated. This training will continue till the
animal attain 9 out of 10 correct choices.
EVALUATION:
Total number of arm entries and alternation behaviour
will be measured. 9/10 correct arm entries signifies
better learning.
Spatial Learning in the
Water Maze
PURPOSE AND
RATIONALE:
 A task was developed where rats learn to swim in a
water tank to find an escape platform hidden under
the water (Morris 1984).
 As there are no proximal cues to mark the position of
the platform, the ability to locate it efficiently will
depend on the use of a configuration of the cues
outside the tank.
 Learning is reflected on the shorter latencies to
PROCEDURE:
Rats are generally used .The
apparatus is a circular water
tank filled to a depth of 20 cm
with 25°C water.
Four points equally distributed
along the perimeter of the tank
serve as starting locations.
The tank is divided in four
equal quadrants and a small
platform (19 cm height) is
located in the centre of one of
the quadrants.
The platform remains in the
same position during the
training days (reference
memory procedure).
The rat is released into the
water and allowed 60–90 s.
to find the platform.
Animals usually receive 2–4
trials per day for 4–5 days
until they escape onto the
platform.
EVALUATION:
The latency to reach the escape platform is measured during the
training days.
A free-swim trial is generally performed after the training days where
the escape platform is removed and the animal is allowed to swim
for 30 s.
Well-trained rats show short latencies.
Electrophysiological
Methods
 Long-Term
Potentiation in
Hippocampal Slices.
 Long Term
Potentiation in Vivo
 Long Latency
Averaged Potentials
Animals with Memory
Deficits
 Memory Deficits After
Cerebral Lesions
 Cognitive Deficits
After Cerebral
Ischemia
 Strains with
Hereditary Memory
Deficits
Genetically Modified
Animals
 Transgenic mice, which
overexpress S100β
 Transgenic Cu/Zn-SOD
mice overexpressing the
gene encoding
copper/zinc superoxide
dismutase
 Mice with a modified β-
amyloid precursor protein
gene
 Transgenic mice cloned by
 Fragile X knockout mouse
 Triple transgenic model of
Alzheimer’s disease
harboring three mutant
genes: β-amyloid
precursor protein
(βAPPSwe), presenilin-1
(PS1M146V), and tau
P301L.
 Alpha7 nicotinic receptor
knockout mice
THANKYOU

More Related Content

What's hot

screening methods for Antiepileptic activity
screening methods for Antiepileptic activityscreening methods for Antiepileptic activity
screening methods for Antiepileptic activitySravanthi Shetty
 
Screening of Anxiolytics
Screening of AnxiolyticsScreening of Anxiolytics
Screening of Anxiolytics
Dr. Advaitha MV
 
Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents
Anurag Chourasia
 
Screening of anti anxiety drugs
Screening of anti anxiety drugsScreening of anti anxiety drugs
Screening of anti anxiety drugsBindu Pulugurtha
 
Screening of antiparkinson agent
Screening of antiparkinson agentScreening of antiparkinson agent
Screening of antiparkinson agent
SONALPANDE5
 
Screening Models of Antidepressants Drugs
Screening Models of Antidepressants DrugsScreening Models of Antidepressants Drugs
Screening Models of Antidepressants Drugs
KomalSingh301
 
SCREENING OF DRUGS USED IN ANTIARRYTHMIA
SCREENING OF DRUGS USED IN ANTIARRYTHMIASCREENING OF DRUGS USED IN ANTIARRYTHMIA
SCREENING OF DRUGS USED IN ANTIARRYTHMIA
SreyaRathnaj
 
Screening Models of Anti-Inflammatory Drugs
Screening Models of Anti-Inflammatory DrugsScreening Models of Anti-Inflammatory Drugs
Screening Models of Anti-Inflammatory Drugs
Anupam dubey
 
Screening models of Anti diabetics.
Screening models of Anti diabetics.Screening models of Anti diabetics.
Screening of anti ulcer drugs
Screening of anti ulcer drugsScreening of anti ulcer drugs
Screening of anti ulcer drugs
Dr Roohana Hasan
 
Screening of antihypertensive agents
Screening of antihypertensive agentsScreening of antihypertensive agents
Screening of antihypertensive agentsKanthlal SK
 
Screening of analgesics
Screening of analgesics Screening of analgesics
Screening of analgesics
Asma Ashraf
 
Screening of antiepileptic drugs
Screening of antiepileptic drugsScreening of antiepileptic drugs
Screening of antiepileptic drugs
Kanthlal SK
 
Drug screening methods for antiarrhythmic agents
Drug screening methods for antiarrhythmic agentsDrug screening methods for antiarrhythmic agents
Drug screening methods for antiarrhythmic agents
Dr. Abhishek Vyas
 
Cns stimulants and depressants screening models
Cns stimulants and depressants screening modelsCns stimulants and depressants screening models
Cns stimulants and depressants screening models
DRASHTI PATEL
 
Multiple sclerosis screening methods
Multiple sclerosis screening methodsMultiple sclerosis screening methods
Multiple sclerosis screening methods
mohamed abusalih
 
Pharmacological screening of Anti-psychotic agents
Pharmacological screening of Anti-psychotic agentsPharmacological screening of Anti-psychotic agents
Pharmacological screening of Anti-psychotic agents
Abin Joy
 
Muscle relaxants by ved prakash
Muscle relaxants by ved prakashMuscle relaxants by ved prakash
Muscle relaxants by ved prakash
vedprakashpanda2
 
Alzheimer models
Alzheimer modelsAlzheimer models
Alzheimer models
Mohammad Muztaba
 
Screening of Diuretics M.PHARM PHARMACOLOGY.
Screening of Diuretics M.PHARM PHARMACOLOGY.Screening of Diuretics M.PHARM PHARMACOLOGY.
Screening of Diuretics M.PHARM PHARMACOLOGY.
S.G.S.S. COLLEGE OF PHARMACY, MANUR
 

What's hot (20)

screening methods for Antiepileptic activity
screening methods for Antiepileptic activityscreening methods for Antiepileptic activity
screening methods for Antiepileptic activity
 
Screening of Anxiolytics
Screening of AnxiolyticsScreening of Anxiolytics
Screening of Anxiolytics
 
Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents
 
Screening of anti anxiety drugs
Screening of anti anxiety drugsScreening of anti anxiety drugs
Screening of anti anxiety drugs
 
Screening of antiparkinson agent
Screening of antiparkinson agentScreening of antiparkinson agent
Screening of antiparkinson agent
 
Screening Models of Antidepressants Drugs
Screening Models of Antidepressants DrugsScreening Models of Antidepressants Drugs
Screening Models of Antidepressants Drugs
 
SCREENING OF DRUGS USED IN ANTIARRYTHMIA
SCREENING OF DRUGS USED IN ANTIARRYTHMIASCREENING OF DRUGS USED IN ANTIARRYTHMIA
SCREENING OF DRUGS USED IN ANTIARRYTHMIA
 
Screening Models of Anti-Inflammatory Drugs
Screening Models of Anti-Inflammatory DrugsScreening Models of Anti-Inflammatory Drugs
Screening Models of Anti-Inflammatory Drugs
 
Screening models of Anti diabetics.
Screening models of Anti diabetics.Screening models of Anti diabetics.
Screening models of Anti diabetics.
 
Screening of anti ulcer drugs
Screening of anti ulcer drugsScreening of anti ulcer drugs
Screening of anti ulcer drugs
 
Screening of antihypertensive agents
Screening of antihypertensive agentsScreening of antihypertensive agents
Screening of antihypertensive agents
 
Screening of analgesics
Screening of analgesics Screening of analgesics
Screening of analgesics
 
Screening of antiepileptic drugs
Screening of antiepileptic drugsScreening of antiepileptic drugs
Screening of antiepileptic drugs
 
Drug screening methods for antiarrhythmic agents
Drug screening methods for antiarrhythmic agentsDrug screening methods for antiarrhythmic agents
Drug screening methods for antiarrhythmic agents
 
Cns stimulants and depressants screening models
Cns stimulants and depressants screening modelsCns stimulants and depressants screening models
Cns stimulants and depressants screening models
 
Multiple sclerosis screening methods
Multiple sclerosis screening methodsMultiple sclerosis screening methods
Multiple sclerosis screening methods
 
Pharmacological screening of Anti-psychotic agents
Pharmacological screening of Anti-psychotic agentsPharmacological screening of Anti-psychotic agents
Pharmacological screening of Anti-psychotic agents
 
Muscle relaxants by ved prakash
Muscle relaxants by ved prakashMuscle relaxants by ved prakash
Muscle relaxants by ved prakash
 
Alzheimer models
Alzheimer modelsAlzheimer models
Alzheimer models
 
Screening of Diuretics M.PHARM PHARMACOLOGY.
Screening of Diuretics M.PHARM PHARMACOLOGY.Screening of Diuretics M.PHARM PHARMACOLOGY.
Screening of Diuretics M.PHARM PHARMACOLOGY.
 

Similar to Screening of anti alzheimers

Preclinical Screening for Alzheimer's
Preclinical Screening for Alzheimer'sPreclinical Screening for Alzheimer's
Preclinical Screening for Alzheimer's
Drx Burade
 
Screening Models of Alzheimers disease.pptx
Screening Models of Alzheimers disease.pptxScreening Models of Alzheimers disease.pptx
Screening Models of Alzheimers disease.pptx
Archna53
 
Screening of anti Alzheimer activity
Screening of anti Alzheimer activityScreening of anti Alzheimer activity
Screening of anti Alzheimer activity
Jaineel Dharod
 
Screening of anxiolytic agents
Screening of anxiolytic agents Screening of anxiolytic agents
Screening of anxiolytic agents
yasmeenmir1
 
Neuro degenerative disorders
Neuro degenerative disordersNeuro degenerative disorders
Neuro degenerative disorders
Ch. Bhargava krishna
 
Screening models of alzheimer’s disease
Screening models of alzheimer’s disease Screening models of alzheimer’s disease
Screening models of alzheimer’s disease
VishnuPrabhakar26
 
Screening of antianxiety drugs
Screening of antianxiety drugsScreening of antianxiety drugs
Screening of antianxiety drugs
Kanthlal SK
 
Screening methods of anxiolytics
Screening methods of anxiolyticsScreening methods of anxiolytics
Screening methods of anxiolytics
Jitendra Agrawal
 
screening model for learning and memory
screening model for learning and memoryscreening model for learning and memory
screening model for learning and memory
Kundlik Rathod
 
Anxiolytics screening methods
Anxiolytics screening methodsAnxiolytics screening methods
Anxiolytics screening methods
Dekollu Suku
 
Light and dark box model 1
Light and dark box model 1Light and dark box model 1
Light and dark box model 1
ANAND SAGAR TIWARI
 
ANXIOLYTICS.pptx
ANXIOLYTICS.pptxANXIOLYTICS.pptx
ANXIOLYTICS.pptx
AdarshGaur8
 
Screening Methods for behavioural and muscle Coordination
 Screening Methods for behavioural and muscle Coordination Screening Methods for behavioural and muscle Coordination
Screening Methods for behavioural and muscle Coordination
pradnya Jagtap
 
Screening of anti-emetic drugs
Screening of anti-emetic drugsScreening of anti-emetic drugs
Screening of anti-emetic drugs
Dr. Prashant Shukla
 
Journal ofExperimental PsychologyVOL. 74, No. 1 MAY 19.docx
Journal ofExperimental PsychologyVOL. 74, No. 1 MAY 19.docxJournal ofExperimental PsychologyVOL. 74, No. 1 MAY 19.docx
Journal ofExperimental PsychologyVOL. 74, No. 1 MAY 19.docx
tawnyataylor528
 
Screening: Drugs Affecting Memory & Learning
Screening: Drugs Affecting Memory & LearningScreening: Drugs Affecting Memory & Learning
Screening: Drugs Affecting Memory & Learning
Shreya Gupta
 
Journalof ExperimentalPsychologyVoL. 74, No. 1MAY 1967.docx
Journalof ExperimentalPsychologyVoL.  74, No. 1MAY 1967.docxJournalof ExperimentalPsychologyVoL.  74, No. 1MAY 1967.docx
Journalof ExperimentalPsychologyVoL. 74, No. 1MAY 1967.docx
croysierkathey
 
Preclinical screening of new substance for pharmacological activity
Preclinical screening of new substance for pharmacological activityPreclinical screening of new substance for pharmacological activity
Preclinical screening of new substance for pharmacological activity
ShrutiGautam18
 
Anxiolytic screening models_utkarsh
Anxiolytic screening models_utkarshAnxiolytic screening models_utkarsh
Anxiolytic screening models_utkarshUtkarsh Alok
 
Anxiolytic poonam ppt.pptx
Anxiolytic poonam ppt.pptxAnxiolytic poonam ppt.pptx
Anxiolytic poonam ppt.pptx
PoonamJoshi51
 

Similar to Screening of anti alzheimers (20)

Preclinical Screening for Alzheimer's
Preclinical Screening for Alzheimer'sPreclinical Screening for Alzheimer's
Preclinical Screening for Alzheimer's
 
Screening Models of Alzheimers disease.pptx
Screening Models of Alzheimers disease.pptxScreening Models of Alzheimers disease.pptx
Screening Models of Alzheimers disease.pptx
 
Screening of anti Alzheimer activity
Screening of anti Alzheimer activityScreening of anti Alzheimer activity
Screening of anti Alzheimer activity
 
Screening of anxiolytic agents
Screening of anxiolytic agents Screening of anxiolytic agents
Screening of anxiolytic agents
 
Neuro degenerative disorders
Neuro degenerative disordersNeuro degenerative disorders
Neuro degenerative disorders
 
Screening models of alzheimer’s disease
Screening models of alzheimer’s disease Screening models of alzheimer’s disease
Screening models of alzheimer’s disease
 
Screening of antianxiety drugs
Screening of antianxiety drugsScreening of antianxiety drugs
Screening of antianxiety drugs
 
Screening methods of anxiolytics
Screening methods of anxiolyticsScreening methods of anxiolytics
Screening methods of anxiolytics
 
screening model for learning and memory
screening model for learning and memoryscreening model for learning and memory
screening model for learning and memory
 
Anxiolytics screening methods
Anxiolytics screening methodsAnxiolytics screening methods
Anxiolytics screening methods
 
Light and dark box model 1
Light and dark box model 1Light and dark box model 1
Light and dark box model 1
 
ANXIOLYTICS.pptx
ANXIOLYTICS.pptxANXIOLYTICS.pptx
ANXIOLYTICS.pptx
 
Screening Methods for behavioural and muscle Coordination
 Screening Methods for behavioural and muscle Coordination Screening Methods for behavioural and muscle Coordination
Screening Methods for behavioural and muscle Coordination
 
Screening of anti-emetic drugs
Screening of anti-emetic drugsScreening of anti-emetic drugs
Screening of anti-emetic drugs
 
Journal ofExperimental PsychologyVOL. 74, No. 1 MAY 19.docx
Journal ofExperimental PsychologyVOL. 74, No. 1 MAY 19.docxJournal ofExperimental PsychologyVOL. 74, No. 1 MAY 19.docx
Journal ofExperimental PsychologyVOL. 74, No. 1 MAY 19.docx
 
Screening: Drugs Affecting Memory & Learning
Screening: Drugs Affecting Memory & LearningScreening: Drugs Affecting Memory & Learning
Screening: Drugs Affecting Memory & Learning
 
Journalof ExperimentalPsychologyVoL. 74, No. 1MAY 1967.docx
Journalof ExperimentalPsychologyVoL.  74, No. 1MAY 1967.docxJournalof ExperimentalPsychologyVoL.  74, No. 1MAY 1967.docx
Journalof ExperimentalPsychologyVoL. 74, No. 1MAY 1967.docx
 
Preclinical screening of new substance for pharmacological activity
Preclinical screening of new substance for pharmacological activityPreclinical screening of new substance for pharmacological activity
Preclinical screening of new substance for pharmacological activity
 
Anxiolytic screening models_utkarsh
Anxiolytic screening models_utkarshAnxiolytic screening models_utkarsh
Anxiolytic screening models_utkarsh
 
Anxiolytic poonam ppt.pptx
Anxiolytic poonam ppt.pptxAnxiolytic poonam ppt.pptx
Anxiolytic poonam ppt.pptx
 

More from Dr Roohana Hasan

Angiogenesis seminar
Angiogenesis seminarAngiogenesis seminar
Angiogenesis seminar
Dr Roohana Hasan
 
Local anaesthetics seminar roohna
Local anaesthetics seminar roohnaLocal anaesthetics seminar roohna
Local anaesthetics seminar roohna
Dr Roohana Hasan
 
Chronotherapeutics final chronopharmacology
Chronotherapeutics final chronopharmacologyChronotherapeutics final chronopharmacology
Chronotherapeutics final chronopharmacology
Dr Roohana Hasan
 
Schedule y by dr.roohna
Schedule y by dr.roohnaSchedule y by dr.roohna
Schedule y by dr.roohna
Dr Roohana Hasan
 
Anticoagulants
AnticoagulantsAnticoagulants
Anticoagulants
Dr Roohana Hasan
 
Pharmacoeconomics 22 feb 2018
Pharmacoeconomics 22 feb 2018Pharmacoeconomics 22 feb 2018
Pharmacoeconomics 22 feb 2018
Dr Roohana Hasan
 
Alzheimers disease
Alzheimers disease Alzheimers disease
Alzheimers disease
Dr Roohana Hasan
 
Chemotherapy of hiv
Chemotherapy of hivChemotherapy of hiv
Chemotherapy of hiv
Dr Roohana Hasan
 
Antiemetics and prokinetics by dr.roohna
Antiemetics and prokinetics by dr.roohnaAntiemetics and prokinetics by dr.roohna
Antiemetics and prokinetics by dr.roohna
Dr Roohana Hasan
 
Glp seminar
Glp  seminarGlp  seminar
Glp seminar
Dr Roohana Hasan
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugs
Dr Roohana Hasan
 
Drug metabolism
Drug metabolismDrug metabolism
Drug metabolism
Dr Roohana Hasan
 
Drug metabolism
Drug metabolismDrug metabolism
Drug metabolism
Dr Roohana Hasan
 
Drug distribution and elimination
Drug distribution and eliminationDrug distribution and elimination
Drug distribution and elimination
Dr Roohana Hasan
 
Cholinergic system and drugs
Cholinergic system and drugsCholinergic system and drugs
Cholinergic system and drugs
Dr Roohana Hasan
 
New drug delivery system by dr.roohna
New drug delivery system by dr.roohnaNew drug delivery system by dr.roohna
New drug delivery system by dr.roohna
Dr Roohana Hasan
 

More from Dr Roohana Hasan (16)

Angiogenesis seminar
Angiogenesis seminarAngiogenesis seminar
Angiogenesis seminar
 
Local anaesthetics seminar roohna
Local anaesthetics seminar roohnaLocal anaesthetics seminar roohna
Local anaesthetics seminar roohna
 
Chronotherapeutics final chronopharmacology
Chronotherapeutics final chronopharmacologyChronotherapeutics final chronopharmacology
Chronotherapeutics final chronopharmacology
 
Schedule y by dr.roohna
Schedule y by dr.roohnaSchedule y by dr.roohna
Schedule y by dr.roohna
 
Anticoagulants
AnticoagulantsAnticoagulants
Anticoagulants
 
Pharmacoeconomics 22 feb 2018
Pharmacoeconomics 22 feb 2018Pharmacoeconomics 22 feb 2018
Pharmacoeconomics 22 feb 2018
 
Alzheimers disease
Alzheimers disease Alzheimers disease
Alzheimers disease
 
Chemotherapy of hiv
Chemotherapy of hivChemotherapy of hiv
Chemotherapy of hiv
 
Antiemetics and prokinetics by dr.roohna
Antiemetics and prokinetics by dr.roohnaAntiemetics and prokinetics by dr.roohna
Antiemetics and prokinetics by dr.roohna
 
Glp seminar
Glp  seminarGlp  seminar
Glp seminar
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugs
 
Drug metabolism
Drug metabolismDrug metabolism
Drug metabolism
 
Drug metabolism
Drug metabolismDrug metabolism
Drug metabolism
 
Drug distribution and elimination
Drug distribution and eliminationDrug distribution and elimination
Drug distribution and elimination
 
Cholinergic system and drugs
Cholinergic system and drugsCholinergic system and drugs
Cholinergic system and drugs
 
New drug delivery system by dr.roohna
New drug delivery system by dr.roohnaNew drug delivery system by dr.roohna
New drug delivery system by dr.roohna
 

Recently uploaded

BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 

Recently uploaded (20)

BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 

Screening of anti alzheimers

  • 1. Presenter – Dr. Roohana Hasan JR3 Moderator- Dr.Afroz Abidi
  • 2. OVERVIEW  Definition  Etiology  Pathophysiology  Pharmacological Agents used in Alzheimers Disease In vitro Models 1. In Vitro Inhibition of AcetylcholineEsterase Activity in Rat Striatum 2. In Vitro Inhibition of ButyrylcholineEsterase Activity in Human Serum 3. [3H]N-Methylscopolamine Binding in the Presence and Absence of Gpp(NH)p 4. Stimulation of Phosphatidylinositol Turnover in Rat Brain Slices 5. [3H]N-Methylcarbamylcholine Binding to Nicotinic Cholinergic Receptors in Rat Frontal Cortex 6. Uncompetitive NMDA Receptor Antagonism. Models for Alzheimers Disease
  • 3. OVERVIEW 1. Step Down. 2. Step through. 3. Scopolamine induced amnesia in mice. 4. Two Compartment Test 5. Up Hill Avoidance In vivo Models 1. Shuttle Box Avoidance (Two- Way Shuttle Box) 2. Jumping Avoidance (One-Way Shuttle Box) 3. Runway Avoidance 1. Open Field Test 2. Radial Arm Maze 3. Y- maze 4. Morris water Maze 1. Conditioned Nictitating Membrane Response in Rabbits 2. Automated Learning and Memory Model in Mice 1. Tau models 2. Aβ-tau axis 3. Secretase models 4. APOE models 5. Axonal transport Passive Avoidance Active Avoidance Discrimination Learning Conditioned Responses Genetic Models
  • 4. INTRODUCTION  Alzheimer's disease (AD) is the most common neurodegenerative disease which has features of progressive impairments in memory, behaviour and cognition and can lead to death.  In addition to the financial burden of AD on health care system, the disease has powerful emotional impact on caregivers and families of those afflicted.
  • 5. Etiology and Risk factors  Strong genetic component  Gender – women, ? Estrogen  Tobacco  Head injury  Obesity  Hypertension  Diabetes  Elevated serum cholesterol  Elevated serum homocysteine  Depression  Lack of intellectual stimulation/education
  • 6. 1. Extracellular deposition of ß- amyloid (Aß) plaques 2. Intraneuronal neurofibrillary tangles. 3. Loss of cortical cholinergic neurones in AD probably accounts for memory impairment. Pathological Hallmarks of Alzheimer’s Disease
  • 7.
  • 8.
  • 9. Formation of plaques and neurofibrillary tangles in Alzheimer’s disease, and sites of action of future drug treatments
  • 11. Inhibitory (Passive) Avoidance  One of the most common animal tests in memory research is the inhibition to imitate activities or learned habits. The term “passive avoidance” is usually employed to describe experiments in which the animal learns to avoid a noxious event by suppressing a particular
  • 12. Purpose and Ratinale Step-down METHOD  An animal (mouse or rat) in an open field spends most of the time close to the walls and in the corners.  When placed on an elevated platform in the center of a rectangular compartment, it steps down almost immediately to the floor to explore the enclosure and to approach the wall.
  • 13. Mice or rats of either sex are used. A rectangular box (50 × 50 cm) with electrifiable grid floor and 35 cm fits over the block. The grid floor is connected to a shock device, which delivers scrambled foot shocks. The actual experiments can be performed in different ways. PROCEDURE:
  • 14. Familiarization: The animal is placed on the platform, released after raising the cylinder, and the latency to descend is measured. After 10 s of exploration, it is returned to the home cage. Learning: Immediately after the animal has descended from the platform an unavoidable footshock is applied (Footshock: 50 Hz; 1.5 mA; 1 s) and the animal is returned to the home cage Retention Test: 24 h after the learning trial the animal is again placed on the platform and the stepdown latency is measured. The test is finished when the animal steps down or remains on the platform (cutoff time: 60 s).
  • 15. EVALUATION: The time of descent during the learning phase and the time during the retention test is measured. A prolongation of the step-down latency is defined as learning.
  • 16. MODIFICATIONS OF THIS METHOD: One of the most common modifications is to induce amnesia in animals. There are different methods to do so including Electroconvulsive shock Scopolamine Alcohol
  • 17. STEP THROUGH METHOD  This test uses normal behavior of mice and rats. These animals avoid bright light and prefer dim illumination.  When placed into a brightly illuminated space connected to a dark enclosure, they rapidly enter the dark compartment and remain there. The standard technique was developed for mice by Jarvik and Kopp (1967) and modified for rats by King and Glasser (1970) PURPOSE AND RATIONALE
  • 18. PROCEDURE: Mice and rats of either sex are used. The test apparatus consists of a small chamber connected to a larger dark chamber via a guillotine door. The test animals are given an acquisition trial followed by a retention trial 24 h later. In the acquisition trial the animal is placed in the illuminated compartment at a maximal distance from the guillotine door, and the latency to enter the dark compartment is measured. Animals that do not step through the door within a cut-off time: 90 s (mice) or 180 s (rats) are not used.
  • 19.  Immediately after the animal enters the dark compartment, the door is shut automatically and an unavoidable footshock (Footshock: 1 mA; 1 s – mice; 1.5 mA; 2 s – rat) is delivered.  The animal is then quickly removed (within 10 s) from the apparatus and put back into its home cage.  The test procedure is repeated with or without
  • 20. EVALUATION:  The time to step-through during the learning phase is measured and the time during the retention test is measured.  In this test a prolongation of the step- through latencies is specific to the experimental situation.  An increase of the step-through latency is defined as learning.
  • 21. UP HILL AVOIDANCE METHOD  Many animal species exhibit a negative geotaxis, i. e. the tendency to orient and move towards the top when placed on a slanted surface.  When placed on a tilted platform with head facing down-hill, rats and mice invariably turn around and move rapidly up the incline. PURPOSE AND RATIONALE:
  • 22. PROCEDURE Rats of both sex were used and maintained under standard conditions. The experimental apparatus is a 50 × 50 cm box with 35 cm high opaque plastic walls. The box can be inclined at different angles. The floor consists of 10 mm diameter stainless steel grid bars placed 13 mm apart. To deliver the tail-shock, a tailelectrode is constructed, consisting of a wire clip connected to a constant current shock source. The animal is first fitted with the tail-electrode and then placed onto the grid with its nose facing down
  • 23. During baseline-trials the animal’s latency to make a 180° turn and initiate the first climbing response is measured. Thereafter the animal is returned to its home cage. During the experimental trials the latencies are measured and additionally a tail-shock (1.5 or 2 mA) was administered contingent on the first climbing response after the 180° turn Immediately after the shock the animal is placed in its home cage. Retest is performed 24 h later
  • 24. EVALUATION:  The latencies are measured. CRITICAL ASSESSMENT OF THE METHOD  The up-hill avoidance technique promises to provide a useful addition to the existing arsenal of inhibitory (passive) avoidance methods.  Its most obvious advantage is that it can be administered to animals debilitated in sensory- motor coordination by pharmacological or surgical treatments that would preclude use of
  • 25. Scopolamine-Induced Amnesia in Mice  The administration of the antimuscarinic agent scopolamine to young human volunteers produces transient memory deficits. Scopolamine has been shown to impair memory retention when given to mice shortly before training in a dark avoidance task. The ability of a range of different cholinergic agonist drugs to reverse the amnesic effects of scopolamine is PURPOSE AND RATIONALE
  • 26. The scopolamine test is performed in groups of 10 male NMRI mice weighing 26–32 g in a one-trial, passive avoidance paradigm. Five min after i.p. administration of 3 mg/kg scopolamine hydrobromide, each mouse is individually placed in the bright part of a twochambered apparatus for training. After a brief orientation period, the mouse enters the second, darker chamber. Once inside the second chamber, the door is closed which prevents the mouse from escaping, and a 1 mA, 1-s foot shock is applied through the grid floor. The mouse is then returned to the home cage. Procedure
  • 27. Twenty-four hours later, testing is performed by placing the animal again in the bright chamber. The latency in entering the second darker chamber within a 5 min test session is measured electronically Whereas untreated control animals enter the darker chamber in the second trial with a latency of about 250 s, treatment with scopolamine reduces the latency to 50 s. The test compounds are administered 90 min before training. A prolonged latency indicates that the animal remembers that it has been punished and, therefore, does avoid the darker chamber.
  • 28. EVALUATION: Using various doses latencies after treatment with test compounds are expressed as percentage of latencies in mice treated with scopolamine only. In some cases, straight dose-response curves can be established whereas with other drugs inverse U-shaped dose-responses are observed. MODIFICATION: Yang et al. (2004) induced learning and memory impairment in mice by treatment with 1-methyl-4- phenyl- 1,2,3,6-tetrahydropyridine (MPTP).
  • 29. Active Avoidance As in other instrumental conditioning paradigms the animal learns to control the administration of the unconditioned stimulus by appropriate reactions to the conditioned stimulus preceding the noxious stimulus. The first stage of avoidance learning is usually escape, whereby a reaction terminates the Active avoidance learning is a fundamental behavioral phenomenon
  • 30. Runway Avoidance  A straightforward avoidance situation features a fixed aversive gradient which can be traversed by the animal.  The shock can be avoided when the safe area is reached within the time allocated. PURPOSE AND RATIONALE:
  • 31. PROCEDURE: The same box as used in the step-through model can be used in this experiment Mice or rats of either sex are used and maintained under standard conditions and handled for several days before the experiment. The apparatus is uniformly illuminated by an overhead light source. A loudspeaker, mounted 50 cm above the start-box, serves for presenting the acoustic conditioned stimulus The footshock is employed by the same source as in the step- through avoidance
  • 32. The animal is allowed to explore the whole apparatus for 5 min. The guillotine door is then closed and the animal is placed into the light starting area. After 10 s the acoustic CS is applied and the door is simultaneously opened. Shock is turned on after 5 s. The CS continuous until the animal reaches the safe area. It is left there for 50–70 s (intertrial interval, ITI) before returned to the same area again The procedure starts again. The training is continued until the animal attains the criterion of 9 avoidances in 10 consecutive trials. On the next day the procedure is repeated until the same learning criterion is reached. The time needed to reach the safe area is measured..
  • 33. EVALUATION:  The time the animal needs to reach the safe area on both days is measured.  In addition, the number of errors (not reaching the safe area) is recorded.
  • 34. Jumping Avoidance (One-Way Shuttle Box) PURPOSE AND RATIONALE:  In order to enhance the start-goal distinction a vertical gradient is introduced which requires the animal to perform a discrete response of an all-or-none character, such as the jump, which clearly differs from the more continuous translational movements required in
  • 35. PROCEDURE: Rats of both sex are used and maintained under standard conditions. The apparatus used consists of a rectangular box 40 × 25 cm with 40 cm high metal walls, an electrifiable grid floor and a Plexiglas ceiling. A 12 × 12 × 25 cm opaque plastic pedestrial, mounted onto one of the narrow walls of the box provides the isolated goal area Flush with the horizontal surface of the pedestal moves a vertical barrier, which can either be retracted to the rear wall of the apparatus to expose the goal area or pushed forward to block access to the goal completely
  • 36. The animal is placed into the apparatus for 5 min with the goal area exposed (barrier retracted). The barrier is then moved forwards and the goal is blocked for 2 s. The first trial starts by exposing the goal area and applying an acoustic CS (1000 Hz, 85 dB). Electric shocks – US (1.0 mA; 50 Hz; 0.5 s) – are applied 5 s later (once per 2 s), and continued together with the CS until the animal jumps onto the platform. After 30 s the barrier pushes the animal off the platform onto the grid floor. The sequence is repeated until the criterion of 10 consecutive avoidances is reached. Retention is tested on the next day until the animal reaches criterion.
  • 37. EVALUATION:  The time the animal needs to reach the safe area on both days is measured.  In addition, the number of errors (not reaching the safe area) is recorded.
  • 39. Spatial Habituation Learning Open Field Test PURPOSE AND RATIONALE:  The open-field test utilizes the natural tendency of rodents to explore novel environments in order to open up new nutrition, reproduction and lodging resources.  Spatial habituation learning is defined as a decrement in reactivity to a novel environment after repeated exposure to that now familiar environment.  This reduction in exploratory behaviors during re- exposures is interpreted in terms of remembering or recognition of the specific physical characteristics of the
  • 40. PROCEDURE: The open-field apparatus is a rectangular chamber made of painted wood or grey PVC. A 25 W red or green light bulb is placed either directly above or beneath the maze to achieve an illumination density at the centre of approximately 0.3 lx. Masking noise is provided by a broad spectrum noise generator (60 dB). Prior to each trial, the apparatus is swept out with water containing 0.1% acetic acid
  • 41. Housing room and the testing location are separated and animals are transported to the testing room 30 min before testing The digitized image of the path taken by each animal is stored. In aged or hypoactive rodents testing is performed during the animals dark phase of day The rodent is placed on the center or in a corner of the open-field for 5–10 minute sessions (mice: up to 20 min, because of the high basal activity level). The animals are re-exposed to the openfield 24 and 96 h after the initial trial
  • 42. EVALUATION:  The exploratory behaviours registered are:  Rearings or vertical activity: the number of times an animal was standing on its hind legs with forelegs in the air or against the wall.  The duration of single rearings as a measure of non-selective attention.  Locomotion or horizontal activity: the distance in centimeters an animal moved.
  • 43. Y-Maze PURPOSE AND RATIONALE:  Measures spatial working memory. It has been designed to make the animal to learn to discriminate between two arms: one illuminated , without shock and other non illuminated with shock and learn to reach the correct arm,the illuminated one.  These kind of experiments are known as Simultaneous Discrimination Learning.
  • 44. PROCEDURE: The naive animal will be allowed to explore the Y maze apparatus for 5minutes at the start of training session. The rat will then be put into the starting chamber. After approximately 5seconds, shock will be applied by switching the unit on or by rotary program selector till the animal reaches the goal in illuminated arm.
  • 45. The animal will then be allowed to stay in that arm for entire inter-trial period. The next program will be selected and the process will be repeated. This training will continue till the animal attain 9 out of 10 correct choices.
  • 46. EVALUATION: Total number of arm entries and alternation behaviour will be measured. 9/10 correct arm entries signifies better learning.
  • 47. Spatial Learning in the Water Maze PURPOSE AND RATIONALE:  A task was developed where rats learn to swim in a water tank to find an escape platform hidden under the water (Morris 1984).  As there are no proximal cues to mark the position of the platform, the ability to locate it efficiently will depend on the use of a configuration of the cues outside the tank.  Learning is reflected on the shorter latencies to
  • 48. PROCEDURE: Rats are generally used .The apparatus is a circular water tank filled to a depth of 20 cm with 25°C water. Four points equally distributed along the perimeter of the tank serve as starting locations. The tank is divided in four equal quadrants and a small platform (19 cm height) is located in the centre of one of the quadrants.
  • 49. The platform remains in the same position during the training days (reference memory procedure). The rat is released into the water and allowed 60–90 s. to find the platform. Animals usually receive 2–4 trials per day for 4–5 days until they escape onto the platform.
  • 50. EVALUATION: The latency to reach the escape platform is measured during the training days. A free-swim trial is generally performed after the training days where the escape platform is removed and the animal is allowed to swim for 30 s. Well-trained rats show short latencies.
  • 51. Electrophysiological Methods  Long-Term Potentiation in Hippocampal Slices.  Long Term Potentiation in Vivo  Long Latency Averaged Potentials
  • 52. Animals with Memory Deficits  Memory Deficits After Cerebral Lesions  Cognitive Deficits After Cerebral Ischemia  Strains with Hereditary Memory Deficits
  • 53. Genetically Modified Animals  Transgenic mice, which overexpress S100β  Transgenic Cu/Zn-SOD mice overexpressing the gene encoding copper/zinc superoxide dismutase  Mice with a modified β- amyloid precursor protein gene  Transgenic mice cloned by  Fragile X knockout mouse  Triple transgenic model of Alzheimer’s disease harboring three mutant genes: β-amyloid precursor protein (βAPPSwe), presenilin-1 (PS1M146V), and tau P301L.  Alpha7 nicotinic receptor knockout mice